Seegene 配当と自社株買い

配当金基準チェック /26

Seegeneは配当を支払う会社で、現在の利回りは3.47%です。次の支払い日は 26th November, 2024で、権利落ち日は27th September, 2024 。

主要情報

3.5%

配当利回り

0.9%

バイバック利回り

総株主利回り	4.4%
将来の配当利回り	3.5%
配当成長	37.4%
次回配当支払日	26 Nov 24
配当落ち日	27 Sep 24
一株当たり配当金	₩800.000
配当性向	126%

最近の配当と自社株買いの更新

Recent updates

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Nov 12

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Aug 10

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Nov 24

決済の安定と成長

配当データの取得

安定した配当: 配当金の支払いは安定していますが、 A096530が配当金を支払っている期間は 10 年未満です。

増加する配当: A096530の配当金は増加していますが、同社は5年間しか配当金を支払っていません。

配当利回り対市場

Seegene 配当利回り対市場

A096530 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (A096530)	3.5%
市場下位25% (KR)	1.2%
市場トップ25% (KR)	3.9%
業界平均 (Biotechs)	0.6%
アナリスト予想 (A096530) (最長3年)	3.5%

注目すべき配当: A096530の配当金 ( 3.47% ) はKR市場の配当金支払者の下位 25% ( 1.24% ) よりも高くなっています。

高配当: A096530の配当金 ( 3.47% ) はKR市場の配当金支払者の上位 25% ( 3.93% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: A096530は高い配当性向 ( 125.5% ) のため、配当金の支払いは利益によって十分にカバーされていません。

株主配当金

キャッシュフローカバレッジ: A096530は合理的な現金配当性向 ( 53.7% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。

Seegene 配当と自社株買い

配当金 基準チェック /26

主要情報

最近の配当と自社株買いの更新

Upcoming dividend of ₩200 per share

Upcoming dividend of ₩200 per share

Upcoming dividend of ₩200 per share

Upcoming dividend of ₩200 per share at 3.5% yield

Upcoming dividend of ₩200 per share at 3.7% yield

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Recent updates

Third quarter 2024 earnings released: EPS: ₩36.00 (vs ₩101 loss in 3Q 2023)

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500

Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval

Full year 2021 earnings: EPS and revenues miss analyst expectations

Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era

Consensus revenue estimates increase by 13%

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order

Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape

Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC

Price target decreased to ₩89,000

Consensus EPS estimates increase to ₩9,305

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at the Medlab Middle East 2021

Investor sentiment improved over the past week

Price target decreased to ₩116,750

Seegene, Inc. Introduces an Exclusive Diagnostic System for Diagnosing Covid-19 Variants

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Investor sentiment deteriorated over the past week

配当金基準チェック /26